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S340 Poster Session IIproduce large amounts of interferon-gamma (IFN-g) under inflam-
matory conditions. Here we address the role of IFN-g production by
Tregs in the course of experimental GvHD.
Methods: In a C57BL/6 into BALB/c mouse model of acute GvHD
we monitored the intracellular cytokine expression of Tregs using
FoxP3-reporter mice (C56BL/6) and congenic markers. We ad-
dressed the role of IFN-g in experimental GvHD i) by employing
the IFN-g blocking mAb XMG1.2 and ii) by adoptive transfer of
Tregs and/ or effector T cells purified from ifng–/– mice. GvHD
severity was monitored by survival, clinical score and histological
analysis.
Results: Co-transferred Tregs in a C57BL/6 into BALB/c model
readily secreted IFN-g but stably remained FoxP3+ and prevented
lethal GvHD. Intracellular staining revealed that at day 4 after trans-
plantation approximately 35% of these allogeneic Tregs produced
IFN-g. In this experimental setting blocking of IFN-g with mAb
completely abolished the protective effect of Tregs and led to early
death from exacerbated GvHD. Of note, we also observed a similar
fatal outcome of experimental GvHD when we co-transferred
ifng–/– Tregs and wild type effector T cells.
Conclusions: Our data suggest that IFN-g should not be regarded
as an adverse pro-inflammatory cytokine under the highly inflamma-
tory environment of acute GvHD since it is required for the protec-
tive action of Tregs. We hypothesize that this may be due to
a deviation of effector T cell profiles towards Th17. In ongoing
experiments we therefore address this issue by employing effector
T cells from il17a–/– / il17f–/– double knock-out mice.522
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Objective: The graft-versus-leukemia (GVL) effect of donor-lym-
phocyte infusions (DLI) is well documented in hematologic malig-
nancies, including multiple myeloma (MM). We evaluated the role
of DLI in persistent or recurrent MM after allogeneic hematopoietic
stem cell transplantation (allo HCT).
Materials and Methods: We identified 23 patients with MM, who
received DLI at UT-MD Anderson Cancer Center between 7/1996
-6/2008. Patients had persistent or recurrent disease after allo HCT,
and were treated with DLI collected from their original allo HCT
donors.
Results: Nineteen patients received DLI from matched related do-
nors (MRD) and 4 from matched unrelated donors (MUD). Median
age at DLI was 51 years (range: 38-62). A total of 33 DLI doses were
administered. Seventeen patients received 1 infusion, 4 patients re-
ceived 2, and 2 patient received 4 infusions. Median interval between
allo HCT and the first DLI was 8.2 months (range: 2.9 to 119.5).
Median follow up from the first DLI was 18 months (range 1-126).
Twenty-six DLI (78%) were given without preceding cytoreductive
chemotherapy. The median DLI dose was 3.5 x 107 CD3+ T cells
(range 0.5 to 14.8 x 107). Overall response rate was 30%, with 10
of 33 DLI doses associated with objective clinical responses (3 CR,
5 VGPR, 2 PR). Thirteen (39%) additional DLI were followed by
stable disease. Median response duration was 5 months (range 2-
10). ORR to DLI in relapsed disease was 10% (2/20), compared to
61% (8/13) for residual disease (p 5 0.0048). Grade II-IV acute
graft-versus-host disease (GVHD) was seen in 6 (26%) patients,
with median onset of 5 weeks fromDLI. None of the patients devel-
oped chronic GVHD after DLI. Median overall survival from the
first DLI was 18.6 months.
Conclusions: DLI is associated with objective clinical responses
patients with relapsed or persistent MM, with a significantly higher
response rate in patients with persistent vs. relapsed disease. The risk
of acute GVHD was low. The role of DLI needs to be furtherexplored in prospective clinical trials for patients with relapsed or
persistent MM.523
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It is known that Graft-vs-Host Disease (GVHD) occurs in
response to minor histocompatibility antigens, but little is known
about the kinetics of donor T cell proliferation and homing in minor
mismatch models of allogeneic hematopoietic cell transplantation
(HCT). This is in contrast tomodels across major histocompatibility
barriers, where early development of GVHDhas been better charac-
terized. Yet, because minor mismatch models are more similar to
clinical HCT, it is critical to understand how GVHD develops
across minor barriers. To investigate temporal and spatial events
of donor T cell activation and homing, side-by-side transplants
were conducted using bone marrow and enriched CD4 and CD8
T cells (Tcon) from donor C56BL/6 mice (H2b) into either major
mismatched Balb/c (H2d), or minor mismatched Balb.b (H2b), irra-
diated recipients. Balb/c mice received 1x106 Tcon while Balb.b
mice received 15x106 Tcon, based on titration experiments. Prolifer-
ation and migration of donor Tcon was monitored using in vivo and
ex vivo bioluminescent imaging, and CFSE labeling. Expression of
T cell activation and homing markers was examined using flow cy-
tometry analysis of donor CD4 andCD8 cells re-isolated from trans-
planted mice. Donor Tcon from Balb.b mice exhibited significantly
reduced proliferation at both 3 and 6 days post transplant (p\0.01, n
5 43). But, mirroring our earlier findings inmajormismatchmodels,
donor Tcon in the minor model homed to nodal sites by day 3, fol-
lowed by an exit to tissues by day 6, albeit reduced. No significant
differences in the expression of the activation and homing markers
examined were noted by day 3, although there was variation across
tissues and between CD4 and CD8 cells. By day 6, donor T cells
re-isolated from Balb.b recipients had reduced levels of a4b7 and
P-selectin, and increased retention of CD62L. These data support
the idea that early events of donor T cell activation, particularly spa-
tially, are similar across minor and major histocompatiblity barriers,
reinforcing the usefulness of both models as translational research
tools. More importantly, these data suggest that delays in visible
GVHD onset in minor mismatch tranpslants arise from temporal
differences in the effector phase of T cell action, rather than delays
in the initiation phase. These findings support targeting very early
events in T cell activation as the most effective method of reducing
GVHD in clinical settings.524
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Background: cGVHD is a major cause of health problems and mor-
tality after allogeneic HCT. Routine clinical laboratory parameters
are established in outcomes monitoring of systemic inflammatory
or autoimmune disease, but their value in cGVHD is unknown.
To determine the relationship between laboratory markers of
